Skip to main content
Institutional deep-dive - valuation, health, statements

Financial Analysis

Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data

Fundamentals

Elanco Animal Health Inc ELAN

· Materials · Pharmaceutical Preparations

FY2025 10-K, filed 2026-02-24
SEC EDGAR

Filing evidence summary

Constructive evidenceCoverage 3/5 core metrics

10 filing-based checks were evaluable.

Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.

Evidence signals

  • No current rule-based risk flags

    10 filing-based checks were evaluable.

    Why this surfaced

    The full financial analysis shows each value, threshold, and sector limitation.

  • Revenue expanded

    Latest reported annual revenue changed +6.2% from the prior reported annual observation.

    Why this surfaced

    Direction threshold: above +2% constructive; below -2% caution; otherwise monitor. This is not labeled one-year growth when filing periods have a gap. Period end 2025-12-31.

  • Free cash flow was positive

    Latest reported free cash flow was $284M.

    Why this surfaced

    Free cash flow = operating cash flow minus capital expenditures; positive is supporting evidence, not a valuation conclusion. Period end 2025-12-31.

Core trend metrics

Latest annual revenue growth
+6.2%
as of 2025-12-31
Free cash flow
$284M
as of 2025-12-31
Debt / equity
0.57x
as of 2025-12-31

Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.

Where to look next

Risk checks

0of 10 rule-based checks flagged

Financial movement

  • Cash→ flat
  • Long-term debt→ flat
  • Inventory→ flat
  • Receivables→ flat
  • Current assets→ flat

Source & freshness

Source
SEC EDGAR XBRL
Fetched
2026-09-06
Latest period end
2025-12-31
Filings
EDGAR ↗

Reported segment mix

figures as filed · share of the filed sum · change vs the prior period in the same filing
Fiscal year ending 2025-12-3110-K filed 2026-02-24prior period 2024-12-31 from the same filingView filing
By business segment
Revenue
  • Reportable Segment$4.71B
    100.0%
    +6.2% yoy

Members sum to the consolidated $4.71B for this period.

By product or service
Revenue
  • Farm Animal$2.36B
    share n/a
    +5.0% yoy
  • Pet Health$2.3B
    share n/a
    +7.3% yoy
  • Cattle$1.13B
    share n/a
    +11.7% yoy
  • Poultry$858M
    share n/a
    +7.8% yoy
  • Swine$379M
    share n/a
    +3.6% yoy
  • Contract Manufacturing$53M
    share n/a
    +15.2% yoy
  • Aqua$0
    share n/a
    -100.0% yoy

member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.

By geography
Revenue
  • Outside the United States$2.48B
    52.6%
    +3.2% yoy
  • United States$2.23B
    47.4%
    +9.7% yoy

Members sum to the consolidated $4.71B for this period.

Latest quarter
Quarter ending 2026-03-3110-Q filed 2026-05-06prior period 2025-03-31 from the same filingView filing
  • Reportable Segment$1.37B
    100.0%
    +14.9% yoy

Change is against the same quarter a year earlier, as reported in the same 10-Q.

Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.

Peer percentiles

latest fiscal year ending 2025-12-31 · among 4,058 US-listed filers · 782 in Materials
MetricValuevs all filersvs sector
Revenue
latest fiscal-year revenue as filed
$4.7B
79thof 3,301
top third
86thof 522
top third
Revenue growth
latest fiscal-year revenue vs the prior fiscal year
6.2%
50thof 3,137
middle third
48thof 473
middle third
Gross margin
gross profit ÷ revenue
55.0%
71stof 1,603
top third
73rdof 221
top third
Net margin
net income ÷ revenue
-4.9%
35thof 3,263
middle third
58thof 518
middle third
Free-cash-flow margin
(operating cash flow − |capex|) ÷ revenue
6.0%
54thof 2,679
middle third
69thof 433
top third
Return on equity
net income ÷ stockholders' equity (positive equity only)
-3.5%
39thof 3,577
middle third
73rdof 701
top third
Stock comp ÷ revenue
stock-based compensation ÷ revenue · lower is ranked higher
1.4%
58thof 2,895
middle third
71stof 476
top third
Days sales outstanding
receivables ÷ revenue × 365 · lower is ranked higher
68 days
29thof 2,398
bottom third
35thof 387
middle third
Net debt ÷ operating cash flow
net debt ÷ operating cash flow (OCF > 0) · lower is ranked higher
5.7×
23rdof 1,547
bottom third
17thof 145
bottom third
Cash-flow accrual ratio
(net income − operating cash flow) ÷ average total assets · lower is ranked higher
-6.1%
62ndof 2,770
middle third
54thof 461
middle third
Balance-sheet accrual ratio
change in net operating assets ÷ average net operating assets · lower is ranked higher
-1.9%
68thof 2,345
top third
61stof 399
middle third

Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.

Earnings quality

latest fiscal year ending 2025-12-31 · accruals and cash conversion as filed
Cash conversion
-
operating cash flow ÷ net income, latest fiscal year
Cash-flow accrual ratio
-6.1%
(net income − operating cash flow) ÷ average total assets
Balance-sheet accrual ratio
-1.9%
change in net operating assets ÷ average net operating assets
Cash-backed years
5 of 5
fiscal years where operating cash flow met or exceeded net income
Mean cash conversion
1.60×
across the stored fiscal years with positive net income

Per fiscal year from filed facts: cash conversion = operating cash flow / net income (net income > 0); cash-flow accrual ratio = (net income - operating cash flow) / average total assets; balance-sheet accrual ratio = change in net operating assets / average net operating assets, NOA = (assets - cash) - (liabilities - debt). Descriptive; a missing input yields a missing ratio. High accrual ratios and cash conversion well below one are the measures the accruals literature associates with less persistent earnings; they are screens to read the cash-flow statement with, not conclusions. The per-year series is part of Pro risk analysis.

Point-in-time ledger

first-reported vs latest filing · periods since 2020-01-01 · 22 changed periods
Line itemPeriodFirst reportedLatest filingChangeFilings
Net income
NetIncomeLoss
quarter 2022-06-30-$22M
10-Q 2022-08-08
-$10M
10-Q 2023-11-07
+54.5%first · latest · 5 filings carry it
Net income
NetIncomeLoss
quarter 2022-09-30-$49M
10-Q 2022-11-08
-$65M
10-Q 2023-11-07
-32.6%first · latest · 3 filings carry it
Capital expenditure
PaymentsToAcquirePropertyPlantAndEquipment
fiscal year 2021-12-31$126M
10-K 2022-02-28
$159M
10-K 2024-02-26
+26.2%first · latest · 3 filings carry it
Capital expenditure
PaymentsToAcquirePropertyPlantAndEquipment
fiscal year 2022-12-31$137M
10-K 2023-03-01
$171M
10-K 2025-02-25
+24.8%first · latest · 3 filings carry it
Long-term debt
LongTermDebt
balance at 2024-06-30$5.68B
10-Q 2024-08-08
$4.32B
10-Q 2025-08-07
-23.9%first · latest
Capital expenditure
PaymentsToAcquirePropertyPlantAndEquipment
quarter 2023-03-31$20M
10-Q 2023-05-09
$24M
10-Q 2024-05-08
+20.0%first · latest
Operating cash flow
NetCashProvidedByUsedInOperatingActivities
quarter 2020-03-31$4.3M
10-Q 2020-05-07
$4M
10-Q 2021-05-07
-7.0%first · latest
Net income
NetIncomeLoss
quarter 2022-03-31$48M
10-Q 2022-05-09
$51M
10-Q 2023-11-07
+6.3%first · latest · 7 filings carry it
Net income
NetIncomeLoss
quarter 2021-03-31-$61M
10-Q 2021-05-07
-$64M
10-K 2023-03-01
-4.9%first · latest · 7 filings carry it
Net income
NetIncomeLoss
quarter 2021-09-30-$104M
10-Q 2021-11-05
-$108M
10-K 2023-03-01
-3.9%first · latest · 3 filings carry it
Capital expenditure
PaymentsToAcquirePropertyPlantAndEquipment
quarter 2020-03-31$12.6M
10-Q 2020-05-07
$13M
10-Q 2021-05-07
+3.2%first · latest
Interest expense
InterestExpense
quarter 2020-03-31$16.5M
10-Q 2020-05-07
$16M
10-Q 2021-05-07
-3.0%first · latest
Net income
NetIncomeLoss
fiscal year 2020-12-31-$560M
10-K 2021-03-01
-$574M
10-K 2023-03-01
-2.5%first · latest · 3 filings carry it
Net income
NetIncomeLoss
fiscal year 2021-12-31-$472M
10-K 2022-02-28
-$483M
10-K 2024-02-26
-2.3%first · latest · 3 filings carry it
Net income
NetIncomeLoss
quarter 2021-06-30-$210M
10-Q 2021-08-09
-$206M
10-K 2023-03-01
+1.9%first · latest · 5 filings carry it
Stock-based compensation
ShareBasedCompensation
fiscal year 2020-12-31$47.7M
10-K 2021-03-01
$47M
10-K 2023-03-01
-1.5%first · latest · 3 filings carry it
Deferred revenue (current)
ContractWithCustomerLiabilityCurrent
balance at 2021-12-31$316M
10-K 2022-02-28
$319M
10-K 2023-03-01
+0.9%first · latest · 5 filings carry it
Stock-based compensation
ShareBasedCompensation
quarter 2020-03-31$11.1M
10-Q 2020-05-07
$11M
10-Q 2021-05-07
-0.9%first · latest
Interest expense
InterestExpense
quarter 2020-06-30$24.8M
10-Q 2020-07-30
$25M
10-Q 2021-08-09
+0.8%first · latest
Depreciation and amortization
DepreciationDepletionAndAmortization
quarter 2020-03-31$81.5M
10-Q 2020-05-07
$82M
10-Q 2021-05-07
+0.6%first · latest
Equity issued
ProceedsFromIssuanceOfCommonStock
fiscal year 2021-12-31$0
10-K 2022-02-28
$500M
10-K 2024-02-26
-first · latest · 3 filings carry it
Equity issued
ProceedsFromIssuanceOfCommonStock
fiscal year 2022-12-31$0
10-K 2023-03-01
$425M
10-K 2024-02-26
-first · latest

First filing reporting each period vs the latest filing carrying it (10-K and 10-Q only, periods since 2020, the extractor's winning tag per concept); a change under 0.5% is treated as rounding. A change can be a restatement, a reclassification or a re-tagging in a later comparative column; the two filings are linked so the reader can see which. Descriptive, not a verdict.

Notes by disclosure type

Not available for ELAN yet: no footnote text blocks on file for this filer in the ingested DERA files.

Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.

Educational content only. Not financial advice. TrendNalysis provides educational and informational financial analysis built from public SEC filings and economic data (FRED, BLS). It is not financial, investment, tax, or legal advice and is not a recommendation to buy or sell any security. Market pricing is not currently included. Past performance does not guarantee future results. Always do your own research and consult a licensed financial professional before investing.